EUVIMEDEUVIMED entdecken
Open Access

Targeted NAD+ repletion via biomimetic nanoparticle enables simultaneous management of intimal hyperplasia and accelerated re-endothelialization: A proof-of-concept study toward next-generation of endothelium-protective, anti-restenotic therapy

Li Yin, Yao Tong, Ruosen Xie, Zhanpeng Zhang, Zain Husain Islam, Kaijie Zhang, Jacobus Burger, Nicholas Hoyt, Eric William Kent, William Aaron Marcum, Campbell Johnston, Rohan Kanchetty und 6 weitere

Journal of Controlled Release · 2024

DOI: 10.1016/j.jconrel.2024.10.045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Li Yin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60603, USA; Department of Surgery, School of Medicine, Unive…. Hauptthemen laut MEDLINE: Hyperplasia, NAD, Nanoparticles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endovascular interventions often fail due to restenosis, primarily caused by smooth muscle cell (SMC) proliferation, leading to intimal hyperplasia (IH). Current strategies to prevent restenosis are far from perfect and impose significant collateral damage on the fragile endothelial cell (EC), causing profound thrombotic risks. Nicotinamide adenine dinucleotide (NAD+) is a co-enzyme and signaling substrate implicated in redox and metabolic homeostasis, with a pleiotropic role in protecting against cardiovascular diseases. However, a functional link between NAD+ repletion and the delicate duo of IH and EC regeneration has yet to be established. NAD+ repletion has been historically challenging due to its poor cellular uptake and low bioavailability. We have recently invented the first nanocarrier that enables direct intracellular delivery of NAD+ in vivo. Combining the merits of this prototypic NAD+-loaded calcium phosphate (CaP) nanoparticle (NP) and biomimetic surface functionalization, we created a biomimetic P-NAD+-NP with platelet membrane coating, which enabled an injectable modality that targets IH with excellent biocompatibility. Using human cell primary culture, we demonstrated the benefits of NP-assisted NAD+ repletion in selectively inhibiting the excessive proliferation of aortic SMC, while differentially protecting aortic EC from apoptosis. Moreover, in a rat balloon angioplasty model, a single-dose treatment with intravenously injected P-NAD+-NP immediately post angioplasty not only mitigated IH, but also accelerated the regeneration of EC (re-endothelialization) in vivo in comparison to control groups (i.e., saline, free NAD+ solution, empty CaP-NP). Collectively, our current study provides proof-of-concept evidence supporting the role of targeted NAD+ repletion nanotherapy in managing restenosis and improving reendothelialization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperplasiaNADNanoparticlesAnimalsHumansMaleBiomimetic MaterialsRats, Sprague-DawleyTunica IntimaEndothelial CellsProof of Concept StudyCell ProliferationCells, CulturedEndothelium, VascularRatsBiomimetics

Stichwörter der Autor:innen

Intimal hyperplasiaNAD+ repletionNanotherapyRe-endothelialization

Substanzen

NAD

Autor:innen und Institutionen

  • Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60603, USA; Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA; Department of Vascu…
  • Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI 53715, USA; Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53715, USA.
  • Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI 53715, USA; Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI 53715, USA.
  • Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
  • Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI 53715, USA.
  • Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI 53715, USA; Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI 53715, USA. Electronic address: s…

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases
  • National Institutes of Health
  • National Heart Lung and Blood Institute

Zitieren

APA

Yin, L., Tong, Y., Xie, R., Zhang, Z., Islam, Z. H., Zhang, K., Burger, J., Hoyt, N., Kent, E. W., Marcum, W. A., Johnston, C., Kanchetty, R., Tetz, Z., Stanisic, S., Huang, Y., Guo, L. W., Gong, S., & Wang, B. (2024). Targeted NAD+ repletion via biomimetic nanoparticle enables simultaneous management of intimal hyperplasia and accelerated re-endothelialization: A proof-of-concept study toward next-generation of endothelium-protective, anti-restenotic therapy. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.10.045

Vancouver

Yin L, Tong Y, Xie R, Zhang Z, Islam ZH, Zhang K, et al. Targeted NAD+ repletion via biomimetic nanoparticle enables simultaneous management of intimal hyperplasia and accelerated re-endothelialization: A proof-of-concept study toward next-generation of endothelium-protective, anti-restenotic therapy. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.10.045

BibTeX
@article{Yin2024,
  author = {Yin, Li and Tong, Yao and Xie, Ruosen and Zhang, Zhanpeng and Islam, Zain Husain and Zhang, Kaijie and Burger, Jacobus and Hoyt, Nicholas and Kent, Eric William and Marcum, William Aaron and Johnston, Campbell and Kanchetty, Rohan and Tetz, Zoe and Stanisic, Sophia and Huang, Yitao and Guo, Lian-Wang and Gong, Shaoqin and Wang, Bowen},
  title = {Targeted NAD+ repletion via biomimetic nanoparticle enables simultaneous management of intimal hyperplasia and accelerated re-endothelialization: A proof-of-concept study toward next-generation of endothelium-protective, anti-restenotic therapy},
  journal = {Journal of Controlled Release},
  year = {2024},
  doi = {10.1016/j.jconrel.2024.10.045}
}
Kostenlos starten →